Haleon (HLN) Notes Payables (2021 - 2026)

Haleon's (HLN) quarterly Notes Payables came in at -$2.6 billion in Q2 2026, down 135.02% on a QoQ basis from -$1.1 billion in Q4 2025.

Haleon (HLN) Notes Payables (2021 - 2026) Analysis & Trends

Haleon (HLN) has 6 years of Notes Payables data on file, last reported at -$2.6 billion in Q2 2026.

Quarterly Notes Payables changed N/A year-over-year to -$2.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$2.6 billion (changed N/A YoY) and the FY2025 annual result came in at -$1.1 billion, up 41.5% from the prior year.
Notes Payables slipped to -$2.6 billion in Q2 2026, from -$1.1 billion in the prior quarter.
In the past five years, Notes Payables ranged from a high of -$55.2 million in Q4 2024 to a low of -$2.6 billion in Q2 2026.
A 5-year average of -$878.5 million and a median of -$418.1 million in 2022 frame the typical range for Notes Payables.
Annual changes were most pronounced in 2023 — Notes Payables rose 27.52% — and 2025, when it tumbled 1929.47%.
Tracing HLN's Notes Payables over 5 years: stood at -$85.6 million in 2022, then climbed by 27.52% to -$62.1 million in 2023, then increased by 11.07% to -$55.2 million in 2024, then plunged by 1929.47% to -$1.1 billion in 2025, then slumped by 135.02% to -$2.6 billion in 2026.
The last three Notes Payables figures came in at -$2.6 billion (Q2 2026), -$1.1 billion (Q4 2025), and -$55.2 million (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn

Download Data